RT Journal Article
A1 Greene, Stephen J.
A1 Butler, Javed
A1 Fonarow, Gregg C.
T1 Simultaneous or Rapid Sequence Initiation of Quadruple Medical Therapy for Heart Failure—Optimizing Therapy With the Need for Speed
JF JAMA Cardiology
JO JAMA Cardiol
YR 2021
DO 10.1001/jamacardio.2021.0496
VO 6
IS 7
SP 743
OP 744
SN 2380-6583
AB Many eligible patients with heart failure (HF) with reduced ejection fraction (HFrEF) never receive therapies shown to extend survival or receive them with much delay. Multiple recent successes in pharmacotherapy for HFrEF provide impetus for embracing change in HFrEF treatment in clinical practice. Quadruple therapy with an angiotensin receptor–neprilsyin inhibitor (ARNI), evidence-based β-blocker, mineralocorticoid receptor antagonist (MRA), and sodium glucose cotransporter 2 inhibitor (SGLT2i) may reduce risk of death by 73% over 2 years. Herein, we present the case for simultaneous or rapid sequence initiation of these 4 lifesaving therapies (Figure).
RD 6/2/2024
UL https://doi.org/10.1001/jamacardio.2021.0496